Evidence map›Paper›PMID 38041763›Full record

ArticleDigestive diseases and sciences2024

Estimate of Increase in Colorectal Cancer Diagnoses with Expansion of Fecal Immunochemical Testing in an Urban Safety-Net Population.

James J Connolly, Heidi S Ahmed, Enoch C Chung, Howard J Cabral, Alessandra Nagar, Abigail Tami, Paul C Schroy, Arpan Mohanty

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

James J ConnollySection of Gastroenterology, Boston Medical Center, 85 E. Concord Street, 7th Floor, Boston, MA, 0211, USA.
Heidi S AhmedSection of Gastroenterology, Boston Medical Center, 85 E. Concord Street, 7th Floor, Boston, MA, 0211, USA.
Enoch C ChungBoston University Chobanian & Avedisian School of Medicine, 85 E. Concord Street, 7th Floor, Boston, MA, 0211, USA.
Howard J CabralDepartment of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Alessandra NagarSection of Gastroenterology, Boston Medical Center, 85 E. Concord Street, 7th Floor, Boston, MA, 0211, USA.
Abigail TamiDepartment of Internal Medicine, Boston Medical Center, Boston, MA, USA.
Paul C SchroySection of Gastroenterology, Boston Medical Center, 85 E. Concord Street, 7th Floor, Boston, MA, 0211, USA.
Arpan MohantySection of Gastroenterology, Boston Medical Center, 85 E. Concord Street, 7th Floor, Boston, MA, 0211, USA. amohanty@bu.edu.ORCID http://orcid.org/0000-0002-8408-8075
Boston Medical Center · USBoston University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFecal immunochemical test (FIT) is less effective in detecting advanced adenomas (AA) than colonoscopy. Increase in FIT for colorectal cancer (CRC) screening may lead to an increased number of undetected AAs which may develop into future CRCs.

aimWe determined the potential impact of FIT expansion on missed AAs and future CRC diagnoses in an urban, tertiary-care, safety-net hospital.

methodsCRC and AA diagnoses were identified in patients undergoing colonoscopy for average-risk CRC screening or positive FIT between 2017 and 2019 at Boston Medical Center. Poisson regression modeling was used to estimate the frequency of AAs per year by age group using data from 2017 to 2019, assuming average outpatient volume and proportion of screening colonoscopies. Total number of patients who received FIT was extrapolated from those who underwent colonoscopy for positive FIT. We estimated AAs per year if 'one-time' FIT was used for screening in 75% and 100% of the population and subtracted this from the estimated AAs per year under the Poisson model to determine missed AAs. We used previously described, age and gender specific estimates of the annual progression of AA to CRC.

resultsThe estimated number of CRCs detected per year is 4.6/1785 males and 4.6/2086 females screened. With 75% FIT expansion, we estimate an additional 3.5 (95% CI 1.3, 9.5) and 2.2 (95% CI 0.64, 7.6) CRCs; with 100% FIT expansion, we estimate an additional 7.4 (95% CI 3.7, 14.9) and 4.2 (95% CI 1.7, 10.5) CRCs, in 5 years, in males and females, respectively.

conclusionExpansion of FIT may substantially increase CRC incidence.

Indexed as

ColonoscopyColorectal NeoplasmsEarly Detection of CancerFecesFemaleHumansMaleMass ScreeningOccult BloodAdvanced adenomaColorectal cancer screeningFecal immunochemical testPrediction modelScreening

Identifiers

PMID38041763
OpenAlexW4389265924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.